Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hamza Hashmi

Showing results (81-90 of 99) with videos related to

Pageof 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2025
Immune-MRD status informs tumor-MRD outcome prognostication in patients with multiple myeloma on lenalidomide maintenanceRoss S Firestone, Anish K Simhal, Devin McAvoy, et al.
Journal of Hematology & Oncology|November 10, 2023
Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort studyNarendranath Epperla, Lei Feng, Nirav N Shah, et al.
Blood Cancer Journal|March 21, 2026
Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortiumCindy Varga, Myra Robinson, James A Davis, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Robust CD4<sup>+</sup> CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene AutoleucelEric M Jurgens, Sneha Mitra, Kevin Herrera, et al.
Blood Cancer Journal|April 14, 2026
Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR studyDoris K Hansen, Danai Dima, Hira Mian, et al.
Transplantation and Cellular Therapy|June 4, 2024
Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World ExperienceJack Khouri, Danai Dima, Hong Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2024
Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple MyelomaNico Gagelmann, Danai Dima, Maximilian Merz, et al.
Blood Cancer Journal|August 9, 2023
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapyChristopher J Ferreri, Michelle A T Hildebrandt, Hamza Hashmi, et al.
Blood Advances|October 19, 2023
Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapyLauren C Peres, Laura B Oswald, Christen M Dillard, et al.
Blood Cancer Journal|December 5, 2024
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapyMaximilian Merz, Danai Dima, Hamza Hashmi, et al.
Pageof 10

Showing results (81-90 of 99) with videos related to

Sort By:
Pageof 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2025
Immune-MRD status informs tumor-MRD outcome prognostication in patients with multiple myeloma on lenalidomide maintenanceRoss S Firestone, Anish K Simhal, Devin McAvoy, et al.
Journal of Hematology & Oncology|November 10, 2023
Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort studyNarendranath Epperla, Lei Feng, Nirav N Shah, et al.
Blood Cancer Journal|March 21, 2026
Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortiumCindy Varga, Myra Robinson, James A Davis, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Robust CD4<sup>+</sup> CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene AutoleucelEric M Jurgens, Sneha Mitra, Kevin Herrera, et al.
Blood Cancer Journal|April 14, 2026
Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR studyDoris K Hansen, Danai Dima, Hira Mian, et al.
Transplantation and Cellular Therapy|June 4, 2024
Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World ExperienceJack Khouri, Danai Dima, Hong Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2024
Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple MyelomaNico Gagelmann, Danai Dima, Maximilian Merz, et al.
Blood Cancer Journal|August 9, 2023
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapyChristopher J Ferreri, Michelle A T Hildebrandt, Hamza Hashmi, et al.
Blood Advances|October 19, 2023
Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapyLauren C Peres, Laura B Oswald, Christen M Dillard, et al.
Blood Cancer Journal|December 5, 2024
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapyMaximilian Merz, Danai Dima, Hamza Hashmi, et al.
Pageof 10